Background. Despite some advances, cardiovascular disease (CVD) remains the leading cause of death and healthcare costs in the United States. We therefore developed a comprehensive CVD policy simulation model that identifies cost-effective approaches for reducing CVD burden. This paper aims to: 1) describe our model in detail; and 2) perform model validation analyses. Methods. The model simulates 1,000,000 adults (ages 35 to 80 years) using a variety of CVD-related epidemiological data, including previously calibrated Framinghambased risk scores for coronary heart disease and stroke. We validated our microsimulation model using recent National Health and Nutrition Examination Survey (NHANES) data, with baseline values collected in 1999-2000 and cause-specific mortality follow-up through 2011. Model-based (simulated) results were compared to observed all-cause and CVD-specific mortality data (from NHANES) for the same starting population using survival curves and, in a method not typically used for disease model validation, receiver operating characteristic (ROC) curves. Results. Observed 10-year all-cause mortality in NHANES v. the simulation model was 11.2% (95% CI, 10.3% to 12.2%) v. 10.9%; corresponding results for CVD mortality were 2.2% (1.8% to 2.7%) v. 2.6%. Areas under the ROC curves for model-predicted 10-year all-cause and CVD mortality risks were 0.83 (0.81 to 0.85) and 0.84 (0.81 to 0.88), respectively; corresponding results for 5-year risks were 0.80 (0.77 to 0.83) and 0.81 (0.75 to 0.87), respectively. Limitations. The model is limited by the uncertainties in the data used to estimate its input parameters. Additionally, our validation analyses did not include nonfatal CVD outcomes due to NHANES data limitations.
C ardiovascular disease (CVD) continues to be the leading cause of death and healthcare costs in the United States (US), despite increased knowledge and management of its risk factors. 1 Costeffective decisions regarding the prevention and treatment of CVD will only become more critical as the health and economic burdens of CVD are projected to increase over the next 20 to 30 years. 2, 3 CVD prevention and management policies can derive particular benefit from modeling studies due to the progressive and complex nature of the disease (a multitude of time-varying risk factors, multiple types of CVD with variable impacts on mortality and morbidity) and the multiple layers of potential intervention (screening, treatment initiation, treatment compliance, acute care, long-term care, among others). Many studies have already quantified CVD risk using regression equations, which naturally translate into probabilities for transitioning from a healthy, non-CVD health state to a composite CVD event health state. 4 These risk prediction equations play a major role in CVD prevention efforts, 5 but they do not capture all relevant health and cost outcomes needed to evaluate CVD-related health interventions.
Decision-analytic models can play important roles in guiding policy on a variety of health matters. The advantage of such models lies in their ability to simulate risk health and cost outcomes that would otherwise not be observable or would take several years to develop. Short-term and long-term outcomes can be calculated, and health-improving interventions can be assessed for both comparativeand cost-effectiveness. These models vary in scale and scope; simple decision problems can be sufficiently addressed using decision trees but more complex disease areas (such as CVD) can benefit from larger policy (i.e., multi-use) models. Best practice is to fully document these models (in terms of their structure, equations, parameter values, and assumptions) and to validate these models against relevant epidemiological data to ensure the accuracy and legitimacy of their predictions. 6 Disease model validation, itself, is an emerging methodological field.
We have therefore developed a microsimulation model-the Cardiovascular Disease Policy Model for Risk, Events, Detection, Interventions, Costs, and Trends (CVD PREDICT)-to project the health and cost outcomes, at both the individual and societal levels, of changes in risk factors and treatment status for CVD. This paper aims to satisfy 2 tasks: 1) describe our model in detail; and 2) perform model validation analyses using survival curves and, in a method that has not yet been used for disease model calibration or validation, receiver operating characteristic (ROC) curves. [7] [8] [9] 
METHODS
Our microsimulation model, coded in C++, is the third generation of a simulation model that was originally a cohort model programmed in TreeAge, 10 which was followed by a Microsoft Excel-based microsimulation. 11 The C++ platform allows for more complexity and faster run times compared with the previous iterations of the model. Much research has been done contrasting individualistic microsimulation models with cohortbased Markov models. 12 , 13 We chose to use a microsimulation approach to more accurately model the natural history of CVD. Specifically, critical to our model is the need to store and modify specific CVD risk factors on an individual basis and update individual-level CVD disease history, and this cannot be done on a cohort level. 14 Individuals in the model do not interact with each other or other objects in the model, so it is not as complex as an agent-based model or discrete event simulation. We describe the CVD PREDICT model structure, input parameters, and key data sources here in addition to our methods for validating model performance in terms of predicting CVD and all-cause mortality using survival curves and ROC curve analysis. Full details on model calculations, parameter estimation methods, and data sources are provided in the Appendix.
Model Population
The CVD PREDICT model is populated with a database of individual patients with accompanying risk factor data. The CVD risk factors necessary to run the model are: sex, age, systolic blood pressure, total cholesterol, HDL cholesterol, currently smoking, and diabetes statuses. The model also considers a patient's prior history of having a CVD event and populates these individuals in their respective CVD health states at the start of a model run. Specifically, adult participants from National Health and Nutrition Examination Surveys (NHANES) are sampled with replacement using sample weights to create a representative population of 1,000,000 individuals. The NHANES population is a representative sample for the US general population, which is the target population for most CVD PREDICT model-based analyses. Risk factor distributions are therefore directly embedded in the starting model population because NHANES reports all of the variables needed at baseline to run the CVD PREDICT model.
Model Simulation
The CVD PREDICT model samples from the model population list, taking the initial set of patient risk factor characteristics for a drawn individual and simulating every subsequent year of the person's life using Monte Carlo microsimulation techniques and common random numbers. 15 Each individual is exposed to a series of possible events (such as death from non-CVD causes, experiencing a CVD event, having a procedure done conditional on having a CVD event, dying from a CVD event, and so no) in each model cycle. Whether an individual experiences an event at a given time in the model depends on a random number (i.e., luck) and the probability that that person experiences that event at that time; these probabilities can depend on individual-level characteristics (which is the case for the CHD and stroke risk equations, described in more detail later) or can be fixed across individuals (such as treatment compliance), depending on the nature of these events and the granularity of the data used to estimate these inputs.
Common random numbers facilitate the comparison of interventions (such as alternative medication policies) by holding a given individual's ''luck'' constant across runs; for instance, an individual that happens to die at a very young age due to non-CVD reasons will die at that age for each intervention being evaluated, so that the comparison of outcomes is more related to the signal (the effects of the intervention) and not the noise (an individual's luck). In other words, common random numbers improve computational efficiency when running comparative analyses (such as cost-effectiveness analyses) with microsimulation models by holding stochastic uncertainty constant across counterfactual scenarios. 15 Three main events occur in the yearly time frame: updating of the risk factors (e.g., an increase in systolic blood pressure), potential transitions into a CVD health state, and preventive interventions (e.g. screening, medication, lifestyle modifications). Costs and health state utilities are also accrued for each individual in every (yearly) model cycle. After a given individual's remaining lifespan and CVD history are simulated with the model, a new individual is selected from the model population list and run through the model. Population totals and averages are calculated and stored once a desired number of individuals complete the simulation.
Risk Factors
CVD risk factor updating can occur at each time step, in which an individual's age is increased by one year. Updates to CVD risk factors are based on independent linear regressions based on 9 waves of cross-sectional NHANES data collected between 1973 and 2010. 2 Systolic blood pressure and total cholesterol increase with age on the individual level and decrease with time based on national trends; HDL cholesterol and risk of developing diabetes increase with both age and time. Sex and smoking status (a dichotomous variable for currently smoking) remain unchanged throughout the course of a patient's life.
Health States
The CVD PREDICT model includes the following general health states: Disease Free (DF), Coronary Heart Disease (CHD), Stroke, and Death. The CHD health state is divided into Myocardial Infarction (MI), Angina, and Cardiac Arrest states. The MI and Angina health states are further classified as with and without revascularization, either with percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. At any given point in time, a simulated individual can only be in one health state. We also classify disease states as acute or chronic, with the first year a patient is in a disease state considered acute, and every subsequent year a patient remains in the same disease state as chronic. A patient cannot return to the DF state after transitioning into a chronic CVD state. Figure 1 shows a simplified structure of the model of how a DF individual can transition into other health states.
Individuals with no prior history of CVD are entered into the model as DF, and those with a prior history are entered in as having a chronic state of that particular CVD event. Transitions from DF to CHD or stroke are based on separate Framinghambased risk functions. We previously calibrated these risk functions using target CHD and stroke incidence data from the Framingham Offspring Cohort (observation years 1980 to 2003) and Atherosclerosis Risk in Communities (ARIC, observation years 1987 to 2001) to calibrate the underlying CHD and stroke risk functions used in the simulation model. The results of this disease model calibration exercise are reported elsewhere. 11 Individuals can die from a non-CVD cause while in any health state, as well as a CVD-specific cause while in a CVD state. Individuals can also have repeat CVD events while in a CVD state. Transitions in the model are hierarchical, in which an individual faces the probability of the more severe events before less severe ones. For example, a DF individual would first face the probability of a non-CVD death, then a stroke event, and, finally, a CHD event. Likewise, an individual in a chronic MI state would first face the probability of death (either CVD or non-CVD), then a nonfatal stroke event, and, finally, a repeat nonfatal MI event. If an individual has had multiple CVD events, the individual remains in the health state of the more severe event. Transition probabilities can be age-and/or sex-specific, involve multiple risk factors and disease history variables, or be based on a single probability value for all individuals. These transitions are described in more detail in the Appendix. Table 1 lists key 1-year transition probabilities and their sources for the CVD PREDICT model applied to a US setting. We classify transition probabilities as coming from a health state, such as ''from DF'' or ''from MI''. We briefly describe 5 main types of transitions here: CVD events, non-CVD mortality, acute CVD mortality, chronic CVD mortality, and repeat CVD events. CHD events are further divided into cardiac arrest, MI, and angina health states, each with its own case fatality, quality-of-life, and cost consequences. The proportion of both cardiac arrest and MI were taken from US data, with the remaining proportion assigned to angina. 16, 17 More details on these calculations can be found in the Appendix. Non-CVD mortality was calculated by removing CVD mortality from all-cause life tables. We used sex-specific all-cause mortality life tables from the Centers for Disease Control and Prevention (CDC); age-and sexspecific CVD-specific death rates (also published by the CDC) were subtracted from the life table annual rates to estimate non-CVD mortality rates, which were converted back to annual probabilities.
Transition Probabilities
Acute (within one year of an event) and chronic (all years after the first year of an event) all-cause mortality were modeled separately for each event state. Acute mortality rates from stroke, cardiac arrest, and angina events are taken directly from various observational studies with US sources, or when US data were lacking, from other developed countries. We also accounted for acute CVD mortality for individuals who experience multiple CVD events within a given year (e.g., cardiac arrest following angina in the same year) using point estimates representing the US in published literature. We applied CVD event-specific multipliers to allcause life tables to estimate chronic CVD mortality; these multipliers were sex-specific and were higher for individuals with a history of .1 CVD event. The risks of secondary CVD events were drawn from studies in the US or other developed countries. Table 1 lists these values; the Appendix contains more details on these calculations.
Model Outputs
The CVD PREDICT model keeps track of every CVD event for every individual run through the model, including the number of deaths arising from each type of CVD event, the average life expectancy of those with and without CVD, the number of individuals who have ever had a CVD event, and the yearly prevalence of every disease state. For costeffectiveness analyses, the model outputs average the lifetime per-person discounted costs and qualityadjusted life years (QALYs). The Appendix contains more details on the inputs specific to cost-effectiveness analyses, including probabilistic sensitivity analysis, utility values (Appendix Table A -1), and cost inputs (Appendix Table A -2).
Screening and Medical Treatment Interventions
The CVD PREDICT model incorporates CVD screening based on individual risk factors and/or calculated CVD risk scores. Screening in the model can lead to medical treatment for primary CVD prevention in the general population. Disease-free individuals become eligible for statin and aspirin therapy if they are deemed at high risk for CVD (exceeding a pre-determined threshold, such as .7.5% 10-year ASCVD risk, LDL cholesterol .190 mg/dL, or having type I or II diabetes). Moreover, we modeled treatment eligibility for anti-hypertensive medications if an individual's systolic blood pressure exceeded a certain level (such as .140 mmHg). Each of these 3 types of drugs has its own compliance and initiation rate, and each drug that an individual is on leads to a relative risk reduction of both CHD and stroke. A combination of drugs produces a combined multiplicative effect. The model includes risks and consequences of adverse events associated with taking a statin. The Appendix shows how we modeled older CVD screening guidelines in our validation analyses to better reflect secular trends in treatment eligibility.
The model additionally accounts for secondary prevention medications, which can reduce probabilities of death or another CVD event once an individual is already in a CVD state. We modeled 4 distinct secondary preventions: statins, aspirin, ACE inhibitors, and beta blockers. Like primary prevention methods, each secondary prevention method involves compliance and initiation, and initiation rates differ for those in CHD and stroke states. The Appendix contains additional details on medical intervention used in the CVD PREDICT model (Appendix Table A -3) with attention on treatment effectiveness inputs (Appendix Table A -4) .
Model Validation Analyses
We validated our calibrated simulation model by comparing CVD PREDICT model-predicted allcause and CVD mortality against observed and predicted mortality data from the NHANES 1999-2000 population ages 35 to 80 years at baseline (baseline data collected 1999 to 2000; cause-specific mortality data available through 2011). We used sample weights and restricted our primary analyses to individuals with complete baseline data in the NHANES population. We performed validation analyses with imputed missing baseline values in a sensitivity analysis. The nationally representative model population of one million individuals was created by weighted sampling with replacement from the NHANES 1999-2000 cohort.
The NHANES follow-up mortality data only include categories of death (as opposed to more specific causes of death). Table 2 shows how we defined CVD death for the observed NHANES data and in the simulation model. Model-predicted CVD mortality was defined by summing acute post-event mortality (i.e., any death within the first year of the event) and a percentage (28.2%) of post-event deaths (i.e., any time after the event) due to the separate estimation of acute and post-first year mortality in CVD health states in the model. We calculated the percentage of post-event deaths as caused by CVD based on follow-up data from the NHANES cohort. Specifically, we calculated the percentage of all observed deaths due to CVD out of all deaths observed in the follow-up period (1999 to 2011) for individuals starting with a history of CVD (7.2% of the cohort). We performed this calculation because of how mortality was estimated in chronic CVD states. Specifically, we applied multipliers to allcause life tables for individuals in CHD and stroke health states, which do not allow for parsing of non-CVD-related and CVD-related mortality for individuals that died in these chronic states.
We used the common starting population from NHANES 1999-2000 to generate survival curves for 3 types of follow-up: 1) observed deaths in the NHANES follow-up data; 2) modeled deaths in the simulation model; and 3) projected deaths only using all-cause US life tables from the CDC (i.e., not modeling CVD events or splitting out causes of death). We did not evaluate CVD death for the third method because the life tables include all causes of mortality. We could compare additional projections of 20-and 30-year all-cause mortality and life expectancy for the simulation model and life table projections, but not for the observed NHANES outcomes because the follow-up stopped in 2011. Individuals in the baseline NHANES 1999-2000 population were drawn with (weighted) replacement to create 1,000 bootstrap samples used to derive the 95% CIs for benchmark points (e.g., 5-year and 10year survival) on the observed survival curves. The Hosmer-Lemeshow goodness-of-fit test (Chi-squared statistic, where lower P values suggest worse fit) was used to compare observed to predicted mortality outcomes (10-and 5-year all-cause and CVD mortality).
In addition to generating survival curves, we assessed model validation by comparing CVD PREDICT model-based mortality risk on an individual level to observed outcomes using ROC curve analysis. To do this, first we ran each individual in the baseline population through the CVD PREDICT model 1,000 times over a 10-year time horizon without using common random numbers. For a given individual, their survival varied over the course of these 1,000 model runs due to chance; survival varies across persons in the model due to their individual characteristics (such as age, sex, blood pressure, cholesterol, among others). We calculated the percentages of iterations that a given individual survived 5 or 10 years from all-cause and CVD mortality to estimate their CVD PREDICT model-based 5-year and 10-year mortality risks. After doing this for each individual in the population, we ranked them by their CVD PREDICT model-based mortality risk. These ranks were compared to observed mortality outcomes on an individual basis to generate ROC curves, with individual-level observed 5-and 10-year mortality statuses used as reference standards. The ROC curve plots the sensitivity (the truepositive ratio) against one minus the specificity (the false-positive ratio). For our analyses, a true positive would be an individual predicted to die within a given time frame (5 or 10 years) based on their CVD PREDICT mortality risk ranking who died in the same time frame in the observed NHANES followup data. The CVD PREDICT model was programmed in Microsoft Visual C++ 2005 and all validation analyses were performed using SAS Version 9.4.
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RESULTS

Baseline Population Characteristics
Weighted baseline characteristics for the NHANES 1999-2000 population limited to those with complete baseline data and the corresponding averages for the same population with imputed values are reported in Table 3 . Most (83.2%) individuals in the NHANES, aged 35 to 80 years, had complete data needed for the risk functions used by the CVD PREDICT model. Cholesterol values (14.5% missing) and systolic blood pressure values (11.0% missing) were the most common missing variables in the analytic sample with substantial overlap (8.7% of analytic sample missing both variables). Mortality status, cause of death, and follow-up time information was complete for all individuals except for 9 individuals (0.2% of the analytic sample) who were assumed to be alive at last point of contact but had follow-up times between 5 and 10 years (i.e., these individuals had complete follow-up data for the 5-year analysis but not for the 10-year analysis). within the 95% CIs of observed mortality outcomes, except for the fourth highest risk quintile for CVD mortality, where the CVD PREDICT model predicted more deaths than were observed in the NHANES data, and the 2 lowest risk quintiles for all-cause mortality, where the CVD PREDICT model predicted fewer deaths than were observed in the NHANES data (all Hosmer-Lemeshow, P \ 0.10).
Model Validation
DISCUSSION
We developed a CVD microsimulation model coded in C++ (the CVD PREDICT model) that integrates individual-level risk factors, epidemiologic inputs, separate CHD and stroke risk equations, case fatality risks, screening and treatment interventions, and utility and cost data into a single model. As opposed to a regression-based risk prediction model that is intended to be used in clinical practice, the CVD PREDICT model is a decision analytic model intended to evaluate the comparative-and cost-effectiveness of CVD policies. The model was validated to observed US CVD mortality data from NHANES, fitting within a reasonable range of values.
External validation is an important criterion for assessing the quality and usefulness of disease models, but few CHD policy model have been calibrated or validated. 6, 36, 37 Although there are no common quantitative standards for assessing goodness of fit, 6, 38 the ability of the CVD PREDICT model to match observed outcomes is similar to other recent CVD policy model validation studies. [39] [40] [41] A review of 154 calibrated cancer simulation models showed that 52% of them mentioned model validation; 42 CVD risk functions are rarely validated externally. 43 We leveraged the individual-level longitudinal NHANES data in our validation analyses in 2 ways by generating survival curves as well as ROC curves. The CVD PREDICT model demonstrated excellent external validity by both measures. Mortality outcomes from the CVD PREDICT model mostly fell within 95% CIs based on observed NHANES data (except for CVD mortality near or just over the upper CI years 7 to 10 for CVD mortality), and the AUCs were consistently .0.80. A review of regression-based CVD risk prediction scores found that only 5 out of 17 external validations had AUCs greater than 0.77. 44 The ROC curve approach has not previously been used for validation of disease simulation models (referring here to models such as decision analytic models, Markov models, microsimulation, and so on, as opposed to regression-based risk prediction models), but both methods add important information in terms of model performance. For instance, limiting validation analyses to survival curves could be misleading if the simulation model had the wrong (i.e., lowest-risk) individuals dying over 5 or 10 years but resulted in similar average population-level 5-or 10-year mortality outcomes observed in the validation dataset. This type of individual-level mismatch of outcome predictions could lead to errors when modeling the effects of targeted interventions. Conversely, ROC curves are constructed using rank values; so, high AUC values could be produced for a simulation model that does not predict absolute mortality risk well. The idea of the joint importance of risk calibration (expected outcomes matching observed outcomes) and risk discrimination (area under the ROC curve) has been discussed for regression-based risk prediction models, but our analysis shows this can also be done for simulation models if individual-level follow-up validation data are available. 45, 46 Presenting the ROC curves themselves can inform modelers and/or decision makers on how the simulation model performs in the ''high sensitivity/low specificity'' and ''low sensitivity/high specificity'' regions of the curve, which could be useful if the model is used to evaluate targeted interventions (i.e., interventions target high-or low-risk individuals.)
The CVD Policy Model (formerly the CHD Policy Model) has been used to evaluate the cost-effectiveness of several CVD projection and prevention studies over several decades; this model has been well-validated in previous studies with a focus on replicating treatment effects from anti-hypertensive and statin medication trials. 16, [47] [48] [49] Our CVD PREDICT model differs from the CVD Policy Model in 2 important respects. First, in contrast to the deterministic Markov modeling approach used in the CVD Policy Model, our CVD PREDICT model is a microsimulation (which simulates heterogenous individuals one at a time, as opposed to Markov models which rely on simulating and aggregating the results from multiple ''cells'' of individual profiles). Second, our validation analysis used nationally representative NHANES data and mortality outcomes as opposed to validating to treatment effects from clinical trials. Despite these methodological differences, both models have been found to arrive at similar policy recommendations in related decision-analytic studies, such as expanded treatment eligibility for low-cost statins used in primary CVD prevention in the US, which is some evidence of cross-validation performance for both models. 6, 50, 51 Model-based economic evaluations of CVDrelated health policies are increasingly common and policy-relevant in the US. 52, 53 Specifically, in 2014, the American College of Cardiology/American Heart Association acknowledged that cost-effectiveness should be the basis for determining value in CVD health policies, but noted that the primary barrier to shifting towards valued-based case ''is the lack of high-quality data on cost and value (costeffectiveness) of interventions or procedures used in practice.'' 53 Our simulation is designed to be flexible enough to evaluate a wide range of CVD-related policies as opposed to being a ''single-use'' model, which is why we invested in a rigorous external validation against nationally representative, longitudinal data. 54 Selected examples of previous and potential applications of our model include staged screening for CVD risk, identifying high-risk primary aldosteronism patients eligible for intensive CVD prevention procedures, and population-based policies focusing on important health behaviors, such as diet and exercise. 11, 55, 56 A limitation of our model, as with all other decision-analytic models, is the abundance of data required as input, as well as the uncertainties underlying the data. As documented, we relied on various assumptions for which certain data do not exist. It was also necessary at times to mix epidemiological inputs from non-US settings in our USbased model. There are some aspects of clinical care, such as the use of angiotensin II receptor blockers for blood pressure control, that we do not explicitly model to balance additional model detail against limiting model complexity. Similarly, we did not include several CVD risk factors in our underlying risk functions, such as c-reactive protein and coronary artery calcification, which might improve prediction but increase the data requirements of the model; certainly, these predictors could be evaluated by the model in a similar fashion to studies by Lee and others and Pletcher and others. 48 We also did not explicitly model interactions between individuals, which previous studies have shown to influence CVD risk factors. 59, 60 Our model therefore cannot exactly be expected to perfectly replicate or forecast actual outcomes. We were also limited by not being able to validate to our model any other outcome aside from mortality due to limitations in the NHANES follow-up data.
Along these lines, due to the lack of other data sources, we had to estimate the proportion of allcause mortality due to CVD (28%) for those in chronic CVD states by calculating the percent of all deaths due to CVD among individuals in the NHANES population with history of CVD at baseline. This value (28%) might seem low given national data that show CVD accounts for 31% of all deaths (and one could assume the proportion of deaths due to CVD would be higher among those with a history of CVD); but the proportion of deaths attributable to CVD in the NHANES validation population for those without a history of CVD at baseline was 17%, which suggests CVD might have been underreported as a cause of death in the NHANES data. 1 In any case, this value (28%) does not affect any transitions in the model but, instead, was used to assign a proportion of all-cause mortality experienced in chronic CVD health states to CVD (i.e., it was used for mortality accounting purposes as opposed to driving underlying risk in the model, so it would not affect our all-cause mortality results). There may also be some minor variations between the ICD-10 classification of CVD deaths in the NHANES data and the CVD PREDICT model that could contribute to some differences in CVD mortality, particularly in later years (7 to 10 years from baseline). Although the Hosmer-Lemeshow statistics were significant, we believe these results are not clinically relevant because almost all of the CVD deaths observed in the NHANES population occurred in the highest risk quintile.
Finally, many CVD risk factors and treatments in the US have evolved over the past 30 years; so, although our model might have external validity in the present tense, it might have less predictive ability in future years. The CVD PREDICT model directly updates some risk factors (such as blood pressure and cholesterol) with age and time, but other model inputs (such as case fatality risks) are fixed over time. New treatments could be developed or existing treatment use could change over time, which may also alter projections of CVD burden to the extent that these changes in treatment rates are not captured in the year coefficients for the regressions that update blood pressure and cholesterol values each year in the model. We also do not explicitly model quitter behavior for current smokers. Performing extensive sensitivity and uncertainty analyses is important for these and all model inputs, which is true for all decision-analytic models. 61 We have described the CVD PREDICT model structure, calculations, and data sources in detail and subjected its projections to rigorous tests of external validation that are not commonly performed for similar models. We show that the CVD PREDICT model can predict actual disease outcomes of policy relevance (all-cause and CVD mortality), which should provide some reassurances to decision makers who choose to use the projections and recommendations based on applications of the model.
